Patent expiration can change
the very course of a market. In the case of the asthma therapeutics market however, the impact will be evident,
but not devastating. Leading brands will certainly suffer to a marked degree
with the expiration of key drugs such as Singulair, Advair, and Symbicort.
Despite this, the asthma therapeutics market in the eight leading developed
nations will likely brave the headwinds and register a CAGR of 2.4% between
2013 and 2020.
According to a recent research report, the market for asthma
therapeutics was valued at US$18.4 billion as of 2013, and will expand to an
estimated US$21.7 billion by the end of 2020. Moving forward, stakeholders and
companies can expect a marginal rate of growth in the asthma therapeutics
market, which can be successfully sustained via the launch of innovative and
affordable therapies.
Blow From Asthma Therapeutics Patent Expiration to be Softened
by These Two Important Drivers
The restraining forces in the asthma therapeutics market will be
balanced by two important drivers: The rising prevalence of asthma and new
players foraying into the market.
According to market research analysts, the number of people
suffering from asthma in the world is pegged at to rocket to an alarming 400
million by 2025. The sheer numbers of asthma patients, many of whom are located
in increasingly affluent emerging economies, will create an organic demand for
asthma therapeutics. Encouraged by this hitherto untapped consumer base,
several new entrants are expected to make their presence felt in the asthma
therapeutics market.
These two factors will be important in the long run because they
will prevent the market from reaching a point of stagnation.
Monoclonal Antibodies and
Biologics to Attract Immense Interest from Pharmaceutical Industry
The current pool of asthma therapeutics is seen to be
satisfactory in terms of helping patients manage symptoms. However, there are
still some patients that are unable to effectively control their condition
using currently-available products. As a result, the asthma therapeutics market
carries a small but significant unmet need, which is further compounded by the
pervasiveness of asthma. All of these factors have stirred the interest of
pharmaceutical companies in the asthma therapeutics industry.
Another factor that will greatly benefit the market is the
presence of an asthma therapeutics pipeline teeming with novel molecules. Many
of these promising molecules are currently reported to be in the late-stage of
development. Industry interest is particularly strong in monoclonal antibodies
such as lebrikizumab, mepolizumab, dupilumab and reslizumab – all of which
directly target Interleukins receptors or ILs themselves. These therapies could
provide pioneering treatment for patients suffering from severe eosinophilic
asthma not adequately controlled.
Personalized Therapy Carries Definite Revenue Generation
Opportunity
Personalized therapy—though it caters to a small sub-set of
patients—will be a trend to watch out for in the coming years. Given their high
price tags, revenues from personalized therapy drugs will be higher, and will
possibly steer the market toward faster growth.
All of these factors will fuse together over the next few years
to help alleviate the impact of patent expiration and the resultant generic
erosion.
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Disease
Introduction
2.2 Epidemiology
2.3 Etiology
2.4 Pathophysiology
2.5 Symptoms
2.6 Diagnosis
2.7 Assessment of
Disease Severity
2.8 Treatment
2.9 Treatment
Algorithm
2.10 Treatment
Segments
2.10.1 ICS Monotherapy
for the Maintenance Treatment of Asthma
2.10.2 Singulair
(montelukast sodium) as First-Line Maintenance Therapy
2.10.3 ICS/LABA
Combination Therapy
2.10.4 Add-on
Therapies
3 Marketed Products
3.1 Overview
3.2 ICS for the
Maintenance Treatment of Asthma
3.2.1 Arnuity
(fluticasone furoate) – GSK
3.3 ICS/LABA
Combination Therapy for the Maintenance Treatment of Asthma
3.3.1 Advair
(fluticasone propionate and salmeterol xinafoate) – GSK
3.3.2 Symbicort
(budesonide and formoterol fumarate) – AstraZeneca, Co-Promotion with Astellas
Pharma
3.3.3 Dulera
(mometasone furoate and formoterol fumarate) – Merck
3.3.4 Relvar/Breo
(vilanterol trifenatate and fluticasone furoate) – GlaxoSmithKline/Theravance
3.4 Add-on Therapy to
ICS or ICS/LABA Therapies for the Maintenance Treatment of Asthma
3.4.1 Xolair (omalizumab)
– Novartis and Genentech
3.4.2 Singulair
(montelukast) – Merck
3.4.3 Spiriva
(tiotropium bromide) – Boehringer Ingelheim
3.5 Heat Maps for
Marketed Products
Send An Enquiry : http://www.mrrse.com/enquiry/106
4 Asthma Pipeline
4.1 Overview
4.2 Pipeline Analysis
by Stage of Development, Molecule Type and Program Type
4.3 Pipeline Analysis
by Molecular Target
4.4 Asthma Clinical
Trial Landscape
4.4.1 Clinical Trial
Failure Rates
4.4.2 Clinical Trial
Duration
4.4.3 Clinical Trial
Size
4.4.4 Comparative
Clinical Trial Metrics Analysis
4.5 Promising Pipeline
Molecules
4.5.1 Mepolizumab –
GSK
4.5.2 Reslizumab –
Teva Pharmaceutical
4.5.3 Lebrikizumab –
Roche/Genentech
4.5.4 Dupilumab –
Regeneron Pharmaceuticals in Collaboration with Sanofi
4.5.5 Masitinib – AB
Science
4.6 Heat Map and Competitor
Matrix for Pipeline Products
5 Market Forecast to
2020
5.1 Geographical
Markets
5.2 Global Market
5.3 North America
5.3.1 Treatment Usage
Patterns
5.3.2 Annual Cost of
Therapy
5.3.3 Market Size
5.4 Top Five Countries
of Europe
5.4.1 Treatment Usage
Patterns
5.4.2 Annual Cost of
Therapy
5.4.3 Market Size
5.5 Japan
5.5.1 Treatment Usage
Patterns
5.5.2 Annual Cost of
Therapy
5.5.3 Market Size
5.6 Drivers and
Barriers for the Asthma Market
5.6.1 Drivers
5.6.2 Barriers
6 Strategic
Consolidations
6.1 Co-development
Deals
6.1.1 Sepracor Enters
into Co-Development Agreement with Nycomed for Ciclesonide
6.1.2 NeoStem Enters
into Agreement with University of California to Develop Human Regulatory T
Cells
6.1.3 Amgen Enters
into Co-Development Agreement with AstraZeneca for Five Monoclonal Antibodies
6.2 Licensing Deals
6.2.1 Amgen Enters
into Licensing Agreement with Kyowa Hakko Kirin – Terminated
6.2.2 Mundipharma
Enters into Licensing Agreement with SkyePharma
6.2.3 MAP
Pharmaceuticals Enters into Licensing Agreement with AstraZeneca – Terminated
6.2.4 Orexo Enters
into Licensing Agreement with Janssen Pharmaceuticals – Terminated
6.2.5 Aslan Pharma
Enters into Licensing Agreement with CSL for CSL-334
UpComing
Report :
· Profenofos Market - Global Industry Expert Opinions Analysis,
Emerging Opportunities, Market Size, Share, Growth Drivers, Market Trends,
Statistics And Forecast 2015 – 2020
Profenofos is an organophosphorus insecticide which is used to
kill pests that damage crop and thus, affects the overall agricultural
productivity. Profenofos chemical name is 0-4-bromo-2- chlorophenyl Oethyl
S-propyl phosphorothioate. The molecular weight of profenofos is approximately
373. Profenofos is used as an ovicide and larvicide in order to kill insects
and larvae of various insects. Profenofos intoxication has resulted mainly due
to the accumulation of acetylcholine at the nerve endings. Profenofos is an
amber coloured liquid. Profenofos generally has a garlic-like odour. Profenofos
has a boiling point of 110oC. Profenofos is usually stable at neutral and
slightly acidic conditions however; profenofos turns unstable under alkaline
conditions. Profenofos being highly soluble in organic solvents helps in easy
application of insecticides on plants. Profenofos is highly flammable in nature
owing to the chemical properties of the solvents in which it is dissolved.
· Polyethylene Terephthalate (PET) Resin Market - Global Industry
Expert Opinions Analysis, Emerging Opportunities, Market Size, Share, Growth
Drivers, Market Trends, Statistics And Forecast 2015 – 2020
Polyethylene terephthalate
(PET) is a thermoplastic polymer that belongs to the family of polyester.
Polyethylene terephthalate resin was introduced for commercial use as textile
fiber and film in 1953. Polyethylene terephthalate (PET) in its natural state
is semi-crystalline colorless resin. Polyethylene terephthalate varies from
semi rigid to rigid mainly on the basis of the method used for processing it.
Polyethylene terephthalate is light weight in nature and has good gas barrier
and alcohol barrier properties. PET becomes white when it is exposed to
chloroform and other chemicals such as toluene. Polyethylene terephthalate is
generally manufactured from terephthalic acid or dimethyl terephthalate and
ethylene glycol. PET offers excellent wear resistance, high flexural modulus,
superior dimensional stability and low coefficient of friction.
About Us
Market Research Reports Search Engine (MRRSE) is an
industry-leading database of market intelligence reports. Headquartered in New
York, U.S., MRRSE is driven by a stellar team of research experts and advisors
trained to offer objective advice. Our sophisticated search algorithm returns
results based on the report title, geographical region, publisher, or other
keywords.
MRRSE partners exclusively with leading global publishers to
provide clients single-point access to top-of-the-line market research. MRRSE’s
repository is updated every day to keep its clients ahead of the next new trend
in market research, be it competitive intelligence, product or service trends
or strategic consulting.
Contact
Us:
State
Tower,
90
State Street,
Suite
700,
Albany
NY - 12207
United
States
Tel:
+1-518-618-1030
Email:
sales@mrrse.com
Website:
http://www.mrrse.com/
